#PD1 Ab looks good and safe in active RA Rosnilimab, a Selective and Potent Depleter of Pathogenic T Many failed several Rx already No safety signals compared to another PD1i Proof of benefit in biospecimens too! abst#LB19 #ACR25 @RheumNow @ACRheum #ACRBest https://t.co/TmEOCfuHZU

Biologic choice in PsA: consider factoring in obesity ⚖️ Abstract 2691: In a longitudinal cohort study, obesity associated with ↓ odds of achieving minimal disease activity (MDA) among pts on TNFi, but not with other DMARDs @RheumNow #ACR25 https://t.co/p4KaH6HKYj

TAC+MMF + GC vs TAC +GC in lupus nephritis (target trial emulation): 🔹Higher total renal response w/ TAC + MMF + GC at 12 mo (59.7% vs 33.3%) consistent in ITT & per-protocol 🔹similar adverse events reported (14.6% vs 16.4%) @RheumNow #ACR25 https://t.co/Yuql3O9C8X

Abstract 2690: Food as a Medicine Mediterranean vs low-calorie DASH vs control diet in PsA (multicenter RCT): 🔹 All 3 groups showed significant weight loss & DAPSA by wk 24 🔹 Weight loss not diet type may be the driver of clinical improvement @RheumNow #ACR25 https://t.co/rBS3HR1HXl

#2702 @ClevelandClinic Vascular ultrasound (VUS) for suspected GCA showed excellent specificity (100%) but low sensitivity (21%) compared with 6m confirmed diagnosis. Fair agreement with TAB (κ=0.64). Findings highlight need for standardised VUS protocols in US. @RheumNow #ACR25 https://t.co/LRFpFBnWWz

Older Adults Underrepresented in RCTs Drs. Jiha Lee and Sebastian Sattui discuss abstract 1072, "Inclusion of Older Adults in Pharmacologic Randomized Controlled Clinical Trials of Autoimmune Rheumatic Diseases: A Systematic Review," presented at #ACR25 https://t.co/uzSPH5RbjM https://t.co/94Vw6qUOIL

Sooner May Still Be Too Late: Kidney Biopsies in SLE #ACR25 kicked off with Plenary Session by Michelle Petri (Abstract 0772: Redefining When to Biopsy the Kidney in Patients with SLE. As part of a collaboration with the Accelerating Medicines Partnership, Petri and colleagues https://t.co/bU09vpcDew

In a 5-year EHR-based cohort, PsO patients initiating IL-17i had significantly lower incidence of PsA/IA vs IL-23i, IL-12/23i, or TNFi. IL-17i reduced time with PsA/IA by 45% vs IL-23i, 61% vs IL-12/23i, and 74% vs TNFi. Further research need investigate if IL-17i may delay https://t.co/0PTbXZpLbu

#ACR25 Abstr#2695 Inguinal lymph node biopsies pre- and post-OBI, RTX, BLIN & CD19 CAR-T showed complete tissue depletion with CAR-T. B-cells reduced but often incomplete with protein-based depleters; OBI being the best. Still don’t agree with “immune reset” @RheumNow #ACRBest https://t.co/Sq7m9sXlLP

#2660 In >8000 women, serum urate rose sharply during the menopausal transition, then plateaued after menopause. Hyperuricemia reached 4-5% post-menopause, up to 18% in obesity or low eGFR. Healthy body weight & kidney function pre-menopause may decrease HU later @RheumNow #ACR25 https://t.co/v6ai3lgAd2

kids w 👇 Undifferentiated #systemic #autoinflammatory #disease Rx #IL1i N=33 =boys &girls 3.5 yrs Sx Abst#2151 #ACR25 @ACRheum @RheumNow There are many periodic fever syndromes 🤔some mutations are not yet discovered Access to &use of Anakinra canukinumab Rilonacept https://t.co/IyTx0nFxKC

#ACR25 Please find my video summary on the Phase 3 RCTs results of Ianalumab in moderate to severe disease activity in #Sjogren Disease presented during Late Breaking Abstract session Abstr#LB24 #SjD @RheumNow https://t.co/ngCAglwAO0 https://t.co/PaUYsxhBKS